Trastornos de la glándula suprarrenal: diagnóstico y tratamiento

Lindholm, 2001, Incidence and late prognosis of Cushing’s syndrome: A population-based study, J Clin Endocrinol Metab, 86, 117 Nieman, 2008, The Diagnosis of Cushing’s Syndrome: An Endocrine Society Clinical Practice Guideline, J Clin Endocrinol Metab, 93, 1526, 10.1210/jc.2008-0125 Arnaldi, 2003, Diagnosis and complications of Cushing’s syndrome: a consensus statement, J Clin Endocrinol Metab, 88, 5593, 10.1210/jc.2003-030871 Ambrogio, 2008, Drugs and HPA axis, Pituitary, 11, 219, 10.1007/s11102-008-0114-6 Papanicolaou, 1998, A single midnight serum cortisol measurement distinguishes Cushing’s syndrome from pseudo-Cushing status, J Clin Endocrinol Metab, 83, 1163 Raff, 1998, Late-night salivary cortisol as a screening test for Cushing’s síndrome, J Clin Endocrinol Metab, 83, 2681 Lépez, 2010, Determinación de los niveles de cortisol salival en una muestra de sujetos de Santiago de Chile, Rev Med Chile, 138, 168, 10.4067/S0034-98872010000200004 Kennedy, 1984, Serum cortisol concentrations during low dose dexamethasone suppression test to screen for Cushing’s syndrome, Br Med J (Clin Res Ed), 289, 1188, 10.1136/bmj.289.6453.1188 Findling, 2005, Screening and diagnosis of Cushing’s syndrome, Endocrinol Metab Clin N Am, 34, 385, 10.1016/j.ecl.2005.02.001 Findling, 2006, Cushing’s Syndrome: Important issues in diagnosis and management, J Clin Endocrinol Metab, 91, 3746, 10.1210/jc.2006-0997 Raff, 2003, A physiologic approach to diagnosis of the Cushing‘s Syndrome, Ann Intern Med, 138, 980, 10.7326/0003-4819-138-12-200306170-00010 Biller, 2008, Treatment of adrenocorticotropindependent Cushing’s syndrome: a consensus statement, J Clin Endocrinol Metab, 93, 2454, 10.1210/jc.2007-2734 Colao, 2012, A 12-Month Phase 3 Study of Pasireotide in Cushing’s Disease, N Engl J Med, 366, 914, 10.1056/NEJMoa1105743 Feelders, 2013, Medical Treatment of Cushing’s Disease, J Clin Endocrinol Metab, 98, 425, 10.1210/jc.2012-3126 Fassnacht, 2012, Combination chemotherapy in advanced adrenocortical carcinoma, N Engl J Med, 366, 2189, 10.1056/NEJMoa1200966 Arlt, 2003, Adrenal Insufficiency, Lancet, 361, 1881, 10.1016/S0140-6736(03)13492-7 Betterle, 2002, Autoimmune adrenal insufficiency and autoimmune polyendocrine syndromes: autoantibodies, autoantigens, and their applicability in diagnosis and disease prediction, Endocr Rev, 23, 327, 10.1210/edrv.23.3.0466 Ketchum, 1984, Adrenal dysfunction in asymptomatic patients with adrenocortical autoantibodies, J Clin Endocrinol Metab, 58, 1166, 10.1210/jcem-58-6-1166 Arlt, 2009, The approach to the adult with newly diagnosed adrenal insufficiency, J Clin Endocrinol Metab, 94, 1059, 10.1210/jc.2009-0032 Clark, 1998, Defining the normal cortisol response to the short synacthen test: implications for the investigation of hypothalamicpituitary disorders, Clin Endocrinol (Oxf), 49, 287, 10.1046/j.1365-2265.1998.00555.x Gebre-Medhin, 2000, Oral dehydroepiandrosterone (DHEA) replacement therapy in women with Addison’s disease, Clin Endocrinol (Oxf), 52, 775, 10.1046/j.1365-2265.2000.01017.x Gurnell, 2008, Long-term DHEA replacement in primary adrenal insufficiency: a randomized, controlled trial, J Clin Endocrinol Metab, 93, 400, 10.1210/jc.2007-1134 Parasrampuria, 1998, Quality control of dehydroepiandrosterone dietary supplement products, JAMA, 280, 1565, 10.1001/jama.280.18.1565 Verma, 2010, A pharmacokinetic and pharmacodynamic study of delayed- and extended-release hydrocortisone (ChronocortTM) vs. conventional hydrocortisone (CortefTM) in the treatment of congenital adrenal hyperplasia, Clinical Endocrinology, 72, 441, 10.1111/j.1365-2265.2009.03636.x Løvas, 2009, Glucocorticoid replacement therapy and pharmacogenetics in Addison’s disease: effects on bone, Eur J Endocrinol, 160, 993, 10.1530/EJE-08-0880 Koetz, 2012, Bone mineral density is not significantly reduced in adult patients on low-dose glucocorticoid replacement therapy, J Clin Endocrinol Metab, 97, 85, 10.1210/jc.2011-2036 Giordano, 2009, Metabolic and cardiovascular profile in patients with Addison’s disease under conventional glucocorticoid replacement, J Endocrinol Invest, 32, 917, 10.1007/BF03345773 Tomlinson, 2001, Association between premature mortality and hypopituitarism. West Midlands prospective hypopituitary study group, Lancet, 357, 425, 10.1016/S0140-6736(00)04006-X Bergthorsdottir, 2006, Premature Mortality in Patients with Addison’s Disease: A Population-Based Study, J Clin Endocrinol Metab, 91, 4849, 10.1210/jc.2006-0076 Erichsen, 2009, Normal overall mortality rate in Addison’s disease, but young patients are at risk of premature death, Eur J Endocrinol, 160, 233, 10.1530/EJE-08-0550 Grumbach, 2003, Management of the clinically inapparent adrenal mass (“incidentaloma”), Ann Intern Med, 138, 424, 10.7326/0003-4819-138-5-200303040-00013 Kloos, 1995, Incidentally discovered adrenal masses, Endocr Rev, 16, 460 Hamrahian, 2005, Clinical utility of noncontrast computed tomography attenuation value (Hounsfield Units) to differentiate adrenal adenomas/hyperplasias from nonadenomas: Cleveland Clinic Experience, J Clin Endocrinol Metab, 90, 871, 10.1210/jc.2004-1627 Nieman, 2010, Approach to the Patient with an Adrenal Incidentaloma, J Clin Endocrinol Metab, 95, 4106, 10.1210/jc.2010-0457 Terzolo, 2011, AME Position Statement on adrenal incidentaloma, Eur J Endocrinol, 164, 851, 10.1530/EJE-10-1147 Quayle, 2007, Needle biopsy of incidentally discovered adrenal masses is rarely informative and potentially hazardous, Surgery, 142, 497, 10.1016/j.surg.2007.07.013 Mazzaglia, 2009, Limited value of adrenal biopsy in the evaluation of adrenal neoplasm, Arch Surg, 144, 465, 10.1001/archsurg.2009.59 Toniato, 2009, Surgical versus conservative management for subclinical Cushing syndrome in adrenal incidentalomas: a prospective randomized study, Ann Surg, 249, 388, 10.1097/SLA.0b013e31819a47d2 Sereg, 2009, Atherosclerotic risk factors and complications in patients with non-functioning adrenal adenomas treated with or without adrenalectomy: a long-term follow-up study, Eur J Endocrinol, 160, 647, 10.1530/EJE-08-0707 Sturgeon, 2006, Risk assessment in 457 adrenal cortical carcinomas: How much does tumor size predict the likelihood of malignancy?, J Am Coll Surg, 202, 423, 10.1016/j.jamcollsurg.2005.11.005 Mantero, 2000, A survey on adrenal incidentaloma in Italy, J Clin Endocrinol Metab, 85, 637 Libe, 2002, Long-term follow-up study of patients with adrenal incidentalomas, Eur J Endocrinol, 147, 489, 10.1530/eje.0.1470489 Cawood, 2009, Recommended evaluation of adrenal ncidentalomas is costly, has high false-positive rates and confers a risk of fatal cancer that is similar to the risk of the adrenal lesion becoming malignant; time for a rethink?, E J Endocrinol, 161, 513, 10.1530/EJE-09-0234